Announcement Landmark BioVentures strengthens immunology and oncology non-clinical capabilities through strategic alliance with Axis Bio
Announcement Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy
Announcement SPIMA Therapeutics Launches to Transform Peptide-Based Immunotherapies and Announces Global Licensing Agreement with SATT AxLR